

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christensen, IV, et al.

Serial No.: 10/598,838 Group Art Unit No.: 1625

Filed: 13 September 2006 Examiner: Not Yet Assigned

For: Pyrazolo [3,4-b] Pyridine Compound, and its use as a PDE4 Inhibitor

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

/James M Kanagy/

James M. Kanagy
Attorney for Applicants
Registration No. 29,550

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014
Facsimile (610) 270-5090

N:\JMK\PATAPPS\PB60771\IDS_1449_Jun2007.doc

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. PB60771	APPLICATION NO. 10/598,838
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Christensen, IV, et al.			
<i>(Use several sheets if necessary)</i>		FILING DATE 13 Sept 2006	GROUP 1625		

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
[NR]	US-3,755,340	Aug-73	Hoehn et al.			
[NR]	US-3,833,594	Sep-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
[NR]	US-3,833,598	Sep-74	Denzel et al.			
[NR]	US-3,840,546	Oct-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
[NR]	US-3,856,799	Dec-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
[NR]	US 3 925 388 A	Dec-75	Hoehn et al.			
[NR]	US-3,966,746	Jun-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
[NR]	US-3,979,399	Sep-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
[NR]	US-4,115,394	Sep-78	Hoehn, et al.			
[NR]	US-5,593,997	Jan-97	Dow, Koch and Schulte			
[NR]	US-2005/0043319	Feb-05	Schweighoffer and Guillet			
[NR]	US-2006/0089375A1	Apr-06	Allen, et al.			
[NR]	US-2006/0252790A1	Nov-06	Allen, et al.			
[NR]	US-2007/0111995A1	May-07	Allen, et al.			
[NR]	US 10/598973	Mar-05	Cook, et al.			
[NR]	US 10/598838	Mar-05	Christensen, IV			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
[NR]		CA-1003419	Jan-77	Canada				
[NR]		CH-553 799	Sep-74	Switzerland				
[NR]		EP-0 076 035	Apr-83	EPC				
[NR]		EP-0 180 318	May-86	EPC				
[NR]		GB 141 7489	Dec-73	GB				
[NR]		GB 151 1006	Apr-75	GB				
[NR]		JP-2002-020386	Jan-02	Japan				
[NR]		WO-00/15222	Mar-00	PCT				
[NR]		WO-01/23389A2	Apr-01	PCT				
[NR]		WO-01/44244A1	Jun-01	PCT				
[NR]		WO-02/060900	Aug-02	PCT				
[NR]		WO-02/081463	Oct-02	PCT				
[NR]		WO-02/098878	Dec-02	PCT				
[NR]		WO-03/016563	Feb-03	PCT				
[NR]		WO-04/056823A1	Jul-04	PCT				
[NR]		WO-04/024728A2	Mar-04	PCT				
[NR]		WO-2005/058892	Jun-05	PCT				
[NR]		WO-2005/090348	Sep-05	PCT				
[NR]		WO-2005/090353	Sep-05	PCT				
[NR]		WO-2005/090354	Sep-05	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[NR]	BARE T.M. ET AL.; Synthesis and structure-activity relationships of a series of anxiolytic pyrazolopyridine ester and amide anxiolytic agents; Journal of Medicinal Chemistry; 1989; 32; pages 2561-2573
[NR]	BEER B., ET AL.; "Enhancement of 3H-diazepam binding by SQ 65,396: a novel anti-anxiety agent"; Pharmacology Biochemistry & Behaviour; 1978; 9; pp. 849-851
[NR]	BONDAVALLI F. ET AL; Synthesis, molecular modelling studies, and pharmacological activity of selective A1 receptor antagonists; Journal of Medicinal Chemistry; 2002; 45(22); pages 4875-4887
[NR]	CHAKRAVORTI; Synthesis of Some Isoquinolylpyrazolo[3,4-b]pyridine Derivatives as Possible Antifilarial Agents; Indian J. Chem.; February 1978; Vol. 16B, pp. 161-163
[NR]	CHASIN M., ET AL.; "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009) - a potent new inhibitor of cyclic 3'5'-nucleotide phosphodiesterases"; Biochemical Pharmacology; 1972; 21; pp. 2443-2450
[NR]	CHEMICAL ABSTRACTS REGISTRY – CAS registry number 502143-17-1 which has the laboratory code NSC 235755, 8th April 2003.
[NR]	DALY J. W. ET AL.; 1-methyl-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pages 293-306; Birkhaeuser; Boston US
[NR]	DAVIS A., ET AL.; "Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"; Journal of Computer-Aided Molecular Design; 1987; 1; pp. 97-119
[NR]	DE MELLO, A. ECHEVERRIA, ET AL.; Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis; Journal of Medicinal Chemistry; 2004; 47(22); pages 5427-5432
[NR]	DENZEL TH.; (translation of title: NEW SYNTHESIS OF 1-UNSUBSTITUTED 1H-PYRAZOLO [3,4-b] PYRIDINE-5-CARBOXYLIC ACID ESTERS); Archiv der Pharmazie; 1974; 307(3); pages 177-186
[NR]	GIEMBYCZ M.A.; Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?; Drugs; 2000; 59(2); pages 193-212
[NR]	GLASS II, W. F., ET AL.; "Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors"; Biochemical Pharmacology; 1979; 28; pp. 1107-1112
[NR]	HOEHN H. ET AL.; 1H-pyrazolo[3,4-b]pyridines; Journal of Heterocyclic Chemistry; 1972; 9(2); pages 235-253
[NR]	HOHN H ET AL; "Potential Antidiabetic Agents. Pyrazolo63,4-b]pyridines"; JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 16, no. 12, 1973, pages 1340-1346, XP002097814 ISSN: 0022-2623 page 1343; compound 37
[NR]	HOROWITZ Z. P., ET AL.; "Cyclic AMP and anxiety"; Psychosomatics; 1972; vol. XIII, no. 2; pp. 85-92
[NR]	KRIPALANI K. J. ET AL.; "Biotransformation in the monkey of cartazolate (SQ 65,396), a substituted pyrazolopyridine having anxiolytic activity"; Xenobiotica; 1981; 11(7); pp. 481-488
[NR]	OCHIAI H. ET AL.; Discovery of new orally active phosphodiesterase (PDE4) inhibitors; Chem. Pharm. Bull.; 2004 (stated to have been published online 15 June 2004); 52(9); pages 1098-1104
[NR]	OCHIAI H. ET AL.; Bioorg. Med. Chem. Web Release; 2003
[NR]	OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; Bioorg. Med. Chem.; 2004 (stated to have been available online 20 June 2004); 12(15); pages 4089-4100
[NR]	OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; Bioorg. Med. Chem. Lett., 5th Jan 2004 issue (available as "articles in press" version on or before 4th December 2003, possibly October 2003, via internet); 14(1); pages 29-32
[NR]	PATEL J.B. AND MALICK J.B.; Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent; Eur. J. Pharmacol.; 1982; 78; pages 323-333
[NR]	PATEL J.B., ET AL.; "Pharmacology of pyrazolopyridines"; Pharmacology Biochemistry & Behaviour; 1985; vol. 23; pp. 675-680

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[NR]	POLSON J. B., ET AL.; "Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle"; Biochemical Pharmacology; 1979; 28; pp. 1391-1395
[NR]	RBI 1998, Catalogue no. T-112, Tracazolate"; 1998; page 340
[NR]	SABITHA, ET AL.; A Facile Route to Pyrazolo[3,4-b]Pyridines and [1]Benzopyrano[4',3'-e]Pyrazolo[3,4-b]Pyridines; Indian Institute of Chemical Technology; 1999; 29(4),655-665; Synthetic Communications; India
[NR]	SCHENONE S. ET AL.; Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands; Bioorg. Med. Chem. Lett.; 2001; 11; pages 2529-2531
[NR]	SHI D., ET AL.; Pyrazolopyridines: effect of structural alterations on activity at adenosine- and GABA-A receptors; Drug Development Research; 1997; 42; pages 41-56
[NR]	WEINRYB I., ET AL.; "Studies in vitro and in vivo with SQ-20,009: an inhibitor of cyclic nucleoside phosphodiesterase with central nervous system activity"; Excerpta Med. Int. Congr. Ser.; 1975; 359; pp. 857-865
[NR]	YU G., MASON H.J., ET. AL.; Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction; Journal of Medicinal Chemistry; 2001; 44; pages 1025-1027
EXAMINER	DATE CONSIDERED
[NILOOFAR RAHMANI]	[12/17/2008]

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.